2024 annual financial data
XTL Biopharmaceuticals 2024 Operating margin
XTL Biopharmaceuticals 2024 operating margin with verified reported values.
Direct answer
Operating margin was -481.6%.
Operating income was -2,172,000 USD and net income was -1,027,000 USD.
Operating cash flow was -1,618,000 USD.
Get free XTL Biopharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 451,000 USD
- Operating income
- -2,172,000 USD
- Net income
- -1,027,000 USD
- Operating cash flow
- -1,618,000 USD